Citius Pharmaceuticals Inc vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $53.21. The key difference: First Trust NASDAQ Clean Edge Green Energy Idx Fd is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | QCLN | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | Sector/Thematic |
52-Week High | $1.82 | $68.47 |
52-Week Low | $0.48 | $36.11 |
Enterprise Value | $16.23M | — |
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.765, up 13.0% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong analyst support with 83% buy ratings but faces significant financial challenges including negative earnings, a -823.34% net income margin, and consecutive quarterly EPS misses. Recent news highlights expansion of LYMPHIR cancer treatment commercialization with 78% quarterly growth in new institutional accounts.
While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial losses and negative cash flow from operations present significant investment risks. The company's ability to achieve profitability through its oncology drug commercialization will determine long-term shareholder value creation.
QCLN trades at $53.09, up 2.0% with a bullish technical signal from moving averages. The ETF benefits from clean energy sector momentum driven by data center power demand and global energy security concerns. Recent news highlights clean energy ETF gains amid volatile oil markets, though regulatory challenges and supply chain pressures present headwinds. Key support sits at $51-52 with resistance at $53-55.
The outlook remains positive given structural energy transition trends, but investors face regulatory uncertainty from U.S. permit delays and China trade tensions. Wall Street sentiment leans bullish on clean energy themes, though valuation metrics are unavailable for this ETF. Risks include geopolitical supply chain disruptions and policy shifts affecting renewable project economics.
Trailing returns across standard periods
Latest headlines on both assets
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →